We’ve spent decades mapping the senescence-associated secretory phenotype (SASP), but we’ve largely ignored the immunological blindfold that comes with it. My lab has been tracking a frustrating trend: as we age, soluble NKG2D ligands (sMICA/B and the ULBP family) circulate in our plasma, acting as a competitive decoy that saturates the activating receptors on our Natural Killer cells.

It’s not just that NK cells "tire out"; they’re being functionally silenced by a cloud of their own targets. By shedding these ligands into the extracellular space, senescent cells aren't just surviving—they’re actively blinding the surveillance system meant to clear them. We’re seeing a total failure in ligand-density sensing, leaving the NK cell unable to distinguish a healthy cell from a pre-neoplastic or senescent one.

Why are we still pouring money into bulk exhaustion markers when the real pathology is a physical, steric block at the immune synapse? If we don't clear these decoys, we can't restore immunosurveillance. It's that simple.

I’m moving into a new phase of research: Ligand-Trap Engineering. We’re developing high-affinity, non-signaling antibodies to act as "decoy sinks," clearing soluble ligands from the periphery without triggering systemic inflammation. The goal is to strip the veil off these senescent populations so NK cells can actually see their targets again. We’re essentially recalibrating the immune system’s signal-to-noise ratio.

I’m looking for collaborators in structural biology and proteomic modeling to help map the real-time kinetics of ligand shedding under varying mechanical stress. We need to define the precise threshold where a cell pivots from surface presentation to massive, evasive shedding.

This isn’t just a mechanistic hurdle; it’s the primary bottleneck of longevity. If we can't re-enable the innate system to recognize the "biological junk" we accumulate, every other intervention—senolytics, epigenetic reprogramming, metabolic support—is just a temporary fix in a burning house. We’re building a high-performance engine but leaving the blindfolds on the drivers.

Who’s ready to stop chasing markers and start restoring the kill switch? My lab has the in vitro models; I need someone to help us translate this into a viable, systemic clearing strategy. Let’s talk.